WYZGA MICHAEL S
Transaction: 06/09/2026
BUY
Change
+6,000
Price
$2.78
Filing
06/11/2026
Type
BUY
Tvardi Therapeutics, Inc.
TVRD • Biotechnology
$1.91
▲ +0.06 (+3.24%)
Current price
EarningsLatest report: Mar 31, 2026
HIGHER-RISK PROFILECautionConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.
Market Cap
$17.92M
Growth
-100.0%
Cash Flow
0/5
Trend
Negative
Evidence
Manageable debt level · 0.01Healthy liquidity · 2.86Negative growth trendWeak profitability
Financial data as of: Mar 31, 2026, 12:00 AM UTCLast earnings update: May 8, 2026, 12:00 AM UTCLast profile update: Aug 14, 2026, 1:08 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$1.91
Change3.24%
Shares Out9.38M
Market Cap$17.92M
Enterprise Value$-6.94M
52W Range1.50 - 43.65
Beta0.39
P/E-1.16
P/B1.24
P/FCF-0.73
EV/EBITDA0.45
EV/FCF0.28
Price$1.91
Change3.24%
Shares Out9.38M
Market Cap$17.92M
Enterprise Value$-6.94M
52W Range1.50 - 43.65
Beta0.39
P/E-1.16
P/B1.24
P/FCF-0.73
EV/EBITDA0.45
EV/FCF0.28
Earnings Yield-86.16%
FCF Yield-137.66%
Dividend Yield0.00%
Gross Margin0.00%
Oper. Margin0.00%
Profit Margin0.00%
Debt/Eq0.01
Current Ratio2.86
Quick Ratio2.86
Revenue 5Y-100.00%
Target$8.75
Target Upside358.12%
Target Median$9.50
Target Range3.00 - 13.00
Volume130.17K
Avg Volume2.17M
EPS Surprise-0.08
Investment DNA
How strong this company looks for long-term investors
42
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
76/100
Growth Potential
Revenue and expansion
20/100
Price Attractiveness
Cheap or expensive today
91/100
Why this score▼
Manageable debt level · 0.01Healthy liquidity · 2.86Negative growth trendWeak profitability
Analyst view
Analyst sentiment and price target
Analyst sentiment
Based on 4 analyst votes · 2026-09-05
63/100
Neutral
Bullish
2
Hold
1
Bearish
1
Price Target
2026-08-14
Low
$3.00
Mean
$8.75
Median
$9.50
High
$13.00
Insider Transactions
Recent executive and insider activity
⚠ 1 high-volume insider sell detected
HALL WALLACE L JR
Transaction: 06/09/2026
BUY
Change
+6,000
Price
$2.78
Filing
06/11/2026
Type
BUY
Shah Sujal
Transaction: 06/09/2026
BUY
Change
+6,000
Price
$2.78
Filing
06/11/2026
Type
BUY
| Insider | Type | Change | Price | Transaction | Filing |
|---|---|---|---|---|---|
| WYZGA MICHAEL S | BUY | +6,000 | $2.78 | 06/09/2026 | 06/11/2026 |
| HALL WALLACE L JR | BUY | +6,000 | $2.78 | 06/09/2026 | 06/11/2026 |
| Shah Sujal | BUY | +6,000 | $2.78 | 06/09/2026 | 06/11/2026 |
| Smith Cynthia | BUY | +6,000 | $2.78 | 06/09/2026 | 06/11/2026 |
| Shiff Susan Ph.D. | BUY | +6,000 | $2.78 | 06/09/2026 | 06/11/2026 |
| Alibhai Imran Nizamudin | BUY | +115,000 | $3.90 | 01/29/2026 | 02/02/2026 |
| Kauh John Saewook M.D. | BUY | +45,000 | $3.90 | 01/29/2026 | 02/02/2026 |
| Conn Avi Daniel | BUY | +45,000 | $3.90 | 01/29/2026 | 02/02/2026 |
| O'Brien Stephen Paul | BUY | +15,000 | $3.90 | 01/29/2026 | 02/02/2026 |
| Alibhai Imran Nizamudin | BUY | +47,500 | $4.20 | 12/16/2025 | 12/18/2025 |
| Conn Avi Daniel | BUY | +17,500 | $4.20 | 12/16/2025 | 12/18/2025 |
| Kauh John Saewook M.D. | BUY | +17,500 | $4.20 | 12/16/2025 | 12/18/2025 |
| O'Brien Stephen Paul | BUY | +4,000 | $4.20 | 12/16/2025 | 12/18/2025 |
| Tweardy Samuel David | SELL | -315,658 | Not reported | 07/07/2025 | 08/05/2025 |
| Tweardy Samuel David | OTHER | 0 | Not reported | 04/15/2025 | 05/02/2025 |
| Wirk Shaheen | BUY | +176,030 | Not reported | 04/15/2025 | 05/02/2025 |
| HALL WALLACE L JR | BUY | +44,712 | Not reported | 04/15/2025 | 05/02/2025 |
| HALL WALLACE L JR | BUY | +12,000 | $17.04 | 04/17/2025 | 04/21/2025 |
| Shah Sujal | BUY | +12,000 | $17.04 | 04/17/2025 | 04/21/2025 |
| Smith Cynthia | BUY | +12,000 | $17.04 | 04/17/2025 | 04/21/2025 |